Bicycle Therapeutics plc has released a corporate presentation outlining its progress in developing Bicycle® molecules, a novel class of synthetic peptides designed for precision-guided therapeutics. The company highlighted advancements in its oncology programs, including the development and regulatory pathway for zelenectide pevedotin in metastatic urothelial cancer and a NECTIN4 gene amplification strategy for targeting multiple cancer types. The pipeline also features radiopharmaceutical candidates addressing novel cancer targets such as MT1-MMP and EphA2. Bicycle Therapeutics reported a cash position of $648.3 million as of September 30, 2025, with an expected financial runway into 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.